1. Background {#sec1-1}
=============

The discovery of Acquired Immunodeficiency Syndrome (AIDS) dates back to 1981 when young gay American adults began developing opportunistic infections (OI).[@ref1] Infections such as pneumocystis and Kaposi sarcoma were common among patients with a weakened immune system. In 1983, Professor Luc Montagnier, in collaboration with Professor Françoise Barré-Sinoussi and Professor Robert Gallo in the United States identified the human immunodeficiency virus (HIV) as the pathogen responsible for AIDS.[@ref2],[@ref3]

Since the 1990s, the HIV/AIDS pandemic has been on a rapid increase, especially in sub-Saharan Africa. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2016, one million people died of OI out of the 36.7 million living with HIV.[@ref3]

An OI is an infection caused by a microorganism that is often present in the environment or even in the body, but cannot cause a disease as long as the immune system is preserved. When this immune system becomes compromised, the microorganism seizes the "opportunity" to develop and cause the occurrence of an infection.[@ref4] Most AIDS-related deaths result from these OIs which are often caused by parasites, bacteria, fungi and other viruses.[@ref5] The classification of HIV patients into clinical stages, as proposed by the World Health Organization (WHO), takes into consideration different OI some of which include: seborrheic dermatitis, shingles, respiratory tract infections, oral candidiasis, oral hairy leukoplakia, pulmonary tuberculosis, severe bacterial infections, pneumocystis, recurrent bacterial pneumonia, cerebral toxoplasmosis, cryptosporidiosis and chronic isosporosis, extrapulmonary cryptococcosis, Kaposi sarcoma, extrapulmonary tuberculosis among others.[@ref6] Among the most common AIDS-defining OIs in Latin America, tuberculosis (TB) accounted for 31%, followed by pneumocystis, which accounted for 24%.[@ref7] In Africa, pulmonary tuberculosis is the leading cause of death in HIV-infected patients.[@ref8] In France, pneumocystis is indicative of AIDS in 30% of patients followed by esophageal candidiasis, which accounts for 22%.[@ref8] In Ethiopia, the prevalence of opportunistic infection was found to be 33.6% among HIV patients in the nation's capital, Addis Ababa.[@ref9]

In Cameroon, the seroprevalence rate of HIV is estimated at 4.7% according to the results published by the Demographic and Health Survey and the Multiple Indicators Survey (DHS-MICS 2016).[@ref10] The National AIDS Control Committee (NACC) 2016 report indicates that Cameroon has opted for UNAIDS target 90-90-90 by 2020. This means that 90% of people infected with HIV should know their HIV status; 90% of HIV-positive people should have access to HIV care and treatment; and that 90% of the patients on treatment should have a suppressed viral load (\<1000 copies/mm). An epidemiological report published by NACC in 2018 showed that 268,939 patients were on anti-retroviral treatment (ART) as of June 2018 compared to the 253,343 at the end of December 2017.[@ref11] However, to achieve the 90-90-90 target, a minimum of about 421,256 out of 520,069 people living with HIV (PLWHIV) should have been on treatment by December 2018, According to the same report, 70.7% of those who had done a viral load were virally suppressed while 29.3% had virologic failure.

These patients with virologic failure are, therefore, likely to develop opportunistic infections (OIs). In the same report, the authors mention HIV-TB co-infection and cotrimoxazole prophylaxis, but nothing is said about the situation of all OIs among PLWHIV in Cameroon. Yet, it is OIs that are responsible for the high number of deaths among PLWHIV.

We, therefore, decided to describe the epidemiological profile of OIs in HIV-infected patients followed up in accredited treatment centers (ATCs) and care units (UPEC) in Yaoundé and Douala. Having an in-depth understanding of the epidemiology of opportunistic infections among PLWHIV will enable us to understand the magnitude of the problem. This information will serve as a guide to policy makers when formulating policies and allocating resources to improve the quality of life of PLWHIV and reduce AIDS related mortality.

1.1. Study Objectives {#sec2-1}
---------------------

The objective of this study was to describe the profile of OIs among PLWHIV in Yaounde and Douala--- the two major cities with greatest burden of HIV in Cameroon. Specifically, we set out to describe the profile (age, sex, profession, level of education) of PLWHIV presenting with OIs, determine the relative frequency of the types of OIs among this group of persons and determine the factors associated with OIs among PLWHIV.

2. Methods {#sec1-2}
==========

2.1. Study Design {#sec2-2}
-----------------

This study was a retrospective descriptive and analytical study carried out within a period of seven months in 12 accredited HIV care and treatment centers (ACTs) in the cities of Yaoundé and Douala, Cameroon. We used a stratified sampling method with 3 sampling levels: the city, type of health facility and size of active files. The cities were selected based on convenience while 12 out of the 38 accredited care and treatment units (ACT) were selected randomly with the probability of selection proportionate to size. The number of ACTs were limited at 12 for convenience. We reviewed patient files spanning from January to December 2014 and our analysis was conducted from October 1, 2017 to April 30, 2018.

2.2. Study Population {#sec2-3}
---------------------

Our study population was HIV-positive patients followed up in accredited treatment centers and care units in the cities of Yaounde and Douala. We included all the files of patients who tested positive for HIV in 2014 in the selected treatment centers irrespective of the serotype and whether the patient was on antiretroviral therapy or not. We excluded patient files that did not carry information on date of HIV diagnosis, medical consultation and basic demographic information such as age and sex. We also excluded patients that were transferred from another health facility without a file. The calculation of the sample size was done using the formula below. There were no prevalence studies from the population of interest in Cameroon, therefore, we used the prevalence rate of 48% from a study in Ethiopia with a determined margin of error of 2.5%. Based on this, we determined our minimum sample size to be 1,534.
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2.3. Sampling Technique {#sec2-4}
-----------------------

From the 38 accredited treatment centers and care/treatment units, selection of study participants was done using a stratified sampling method with 3 sampling levels: city (Yaounde or Douala), type of health institution (public/private) and the number of active files. The number of active files in each site was considered small if it was less than or equal to 978, which was the median number of active files in the different sites. For convenience, we selected 12 treatment sites offering antiretroviral treatment in the two cities that had been selected (Yaoundé and Douala). The treatment sites were selected randomly with the probability of selection proportionate to size.

2.4. Data Collection and Analysis {#sec2-5}
---------------------------------

After obtaining all required authorizations, we started by testing our questionnaire in a treatment center that did not participate in the study. This was done at the HIV treatment unit of Cité Verte District Hospital, Yaoundé and all challenges encountered with the questionnaire were addressed. To determine the probing step in each site we divided the cohort by the sample size of the site. Then we selected the patients' files by sampling, respecting the sampling rate defined for each site until the sample size was reached for the chosen site. For example, when the probing step was 6, we randomly chose a number between one and six. The random number was considered the first record in the study. Subsequently, we added six to this number to get the number of the next file, then six to the number of the next file, and so on. If for one reason or another a file was not in place, the next file was taken without changing the pre-established order thereafter. In addition, when searching for information in the medical file, we verified its validity in terms of completeness of data by taking into account the inclusion and exclusion criteria. Every patient file that was selected was studied from the date of opening to the last consultation and any diagnoses of OIs made by the physicians were considered. Patients were said to be symptomatic according to WHO criteria.[@ref27] Records of deceased patients were also exploited. The data collected were entered and analyzed with Epi Info version 3.5.4 (CDC, Atlanta, USA, 2012). Qualitative variables were expressed as percentages while quantitative variables were expressed as medians, means and standard deviation for the assessment of its centrality. The chi-square test was used to compare the percentages and corrected by the Fischer test when the applied conditions were not valid. The means were compared through the student test.

3. Results {#sec1-3}
==========

3.1. Socio-demographic Characteristics of the Study Population {#sec2-6}
--------------------------------------------------------------

We sampled a total of 1,617 subjects in this study and women accounted for 71.2% (1,152). The average age of our participants was 41.27 ± 10.17 years with an age range of 20 to 82years old ([table 1](#T1){ref-type="table"}). Forty four percent (711) of the subjects were single while 28.3% were married. Fifty seven percent of the study participants had received education up to secondary level while 27% were business men and women ([table 2](#T2){ref-type="table"}).

###### 

Distribution by age and sex

  Age range (in years)   Sex          Total         
  ---------------------- ------------ ------------- ------
  20-29                  23 (13.1)    152 (86.9)    175
                                                    
  30-39                  131 (21.8)   470 (78.2)    601
                                                    
  40-49                  178 (35.1)   329 (64.9)    507
                                                    
  ≥ 50                   133 (39.8)   201 (60.2)    334
                                                    
  Total                  465 (28.8)   1152 (72.2)   1617

###### 

Distribution by level of education and profession

  Variables              Frequency   Percentage (%)
  ---------------------- ----------- ----------------
  Level of Education                 
                                     
   No formal education   54          3.3
                                     
   Primary               381         23.6
                                     
   Secondary             922         57
                                     
   University            260         16.1
                                     
  Profession                         
                                     
   Housewife             335         20.7
                                     
   Civil servant         229         14.2
                                     
   Student               132         8.2
                                     
   Trader                435         26.9
                                     
   Others                486         30.1

3.2. Clinical Characteristics of the Study Population {#sec2-7}
-----------------------------------------------------

Eight hundred and ninety-two of our study participants (55.2%) had discovered their HIV serological status after a clinical suspicion by a health care provider while 31.8% were diagnosed during voluntary counselling and testing ([table 3](#T3){ref-type="table"}). Six hundred and thirty-eight participants (44.2%) had a baseline CD4 count of less than 200 copies/mm[@ref3]. In addition, 459 had a recent viral load result with 260 (56.6%) of them being less than 50 copies/mm^3^ ([table 4](#T4){ref-type="table"}). The majority of the participants, 1215 (75.2%) were on WHO's first line regimen.

###### 

Circumstance leading to HIV diagnosis

  Circumstances of HIV diagnosis                      Frequency   Percentage
  --------------------------------------------------- ----------- ------------
  Provider initiated testing and counselling (PITC)   892         55.2
                                                                  
  Voluntary counselling and testing                   514         31.8
                                                                  
  Antenatal consultation (ANC)                        153         9.5
                                                                  
  Premarital counselling and testing                  12          0.7
                                                                  
  Blood donation                                      2           0.1
                                                                  
  Others                                              44          2.7

###### 

Distribution according to CD4 count and viral load

  Variables                                        Frequency   Percentage
  ------------------------------------------------ ----------- ------------
  CD4 count on initiation                                      
                                                               
   0-199/mm^3^                                     638         44.2
                                                               
   200-349/mm^3^                                   470         32.6
                                                               
   ≥ 350/mm^3^                                     334         23.2
                                                               
  First viral load results from after initiation               
                                                               
   0-49 copies                                     18          15.4
                                                               
   50-999 copies                                   29          24.8
                                                               
   ≥ 1000 copies                                   70          59.8
                                                               
  Most recent viral load result                                
                                                               
   0-49 copies                                     260         56.6
                                                               
   50-999 copies                                   133         29.0
                                                               
   ≥ 1000 copies                                   66          14.4

3.3. Characteristics of Patients with at Least One Opportunistic Infection {#sec2-8}
--------------------------------------------------------------------------

A total of 419 participants had at least one OI, 65.2% of them were women, 42.7% were single, 35.1% were within the age range of 40 to 49 years and 78.7% (330) were on first-line antiretroviral (ARV) regimens ([table 5](#T5){ref-type="table"}). Two hundred and forty-six (60.6%) had a baseline CD4 count of less than 200 copies/mm[@ref3]; and 123 had a recent viral load result with 53 (43%) of them being less than 50 copies**/**mm^3^ ([table 6](#T6){ref-type="table"}). The most common opportunistic infections found were shingles (25%), followed by pulmonary tuberculosis (20%) and oral candidiasis (12%) ([table 7](#T7){ref-type="table"}).

###### 

Sociodemographic characteristics of patients with opportunistic infections

  Variables              Frequency (n)   Percentage
  ---------------------- --------------- ------------
  Sex                                    
                                         
   Male                  146             34.8
                                         
   Female                273             65.2
                                         
  Age (years)                            
                                         
   20-29                 28              6.7
                                         
   30-39                 137             32.7
                                         
   40-49                 147             35.1
                                         
   ≥50                   107             25.5
                                         
  Marital status                         
                                         
   Married               119             28.4
                                         
   Widow/widower         38              9.1
                                         
   Divorced              16              3.8
                                         
   Single                179             42.7
                                         
   Concubine             67              16.0
                                         
  Level of Education                     
                                         
   No formal Education   15              3.5
                                         
   Primary               111             26.5
                                         
   Secondary             229             54.7
                                         
   University            64              15.3
                                         
  Profession                             
                                         
   Housewife             91              21.7
                                         
   Civil Servant         60              14.3
                                         
   Student               33              7.9
                                         
   Trader                113             27.0
                                         
   Others                122             29.1

###### 

Clinical manifestation according to the World Health Organization (WHO) staging

  Clinical stage                              Clinical characteristics                 Frequency   Percentage
  ------------------------------------------- ---------------------------------------- ----------- ------------
  Stage 1 n=1 (0.07%)                         Persistent generalized lymphadenopathy   1           0.1
                                                                                                   
  Stade 2 n=401 (29.08%)                      Weight loss \<10%                        186         13.5
                                                                                                   
  Herpes zoster                               130                                      9.4         
                                                                                                   
  Papular pruritic eruptions                  45                                       3.3         
                                                                                                   
  Recurrent oral ulcerations                  11                                       0.8         
                                                                                                   
  Sinusitis                                   10                                       0.7         
                                                                                                   
  Onychomycosis                               8                                        0.6         
                                                                                                   
  Otitis                                      2                                        0.1         
                                                                                                   
  Pharyngitis                                 5                                        0.4         
                                                                                                   
  Seborrheic dermatitis                       4                                        0.3         
                                                                                                   
  Stade 3 n=879 (63.74%)                      Weight loss \>10%                        388         28.1
                                                                                                   
  Unexplained persistent fever \>1 month      158                                      11.5        
                                                                                                   
  Pulmonary TB                                104                                      7.5         
                                                                                                   
  Unexplained persistent diarrhea \>1 month   83                                       6.0         
                                                                                                   
  Oral candidiasis                            63                                       4.6         
                                                                                                   
  Lung infections                             50                                       3.6         
                                                                                                   
  Persistent anemia with HB\<8g/dl            30                                       2.2         
                                                                                                   
  Oral hairy leukoplakia                      1                                        0.1         
                                                                                                   
  Osteoarthritis                              1                                        0.1         
                                                                                                   
  Meningitis                                  1                                        0.1         
                                                                                                   
  Stade 4 n=98 (7.10%)                        Kaposi sarcoma                           30          2.2
                                                                                                   
  Cerebral toxoplasmosis                      25                                       1.8         
                                                                                                   
  Extrapulmonary TB                           20                                       1.5         
                                                                                                   
  Esophageal candidiasis                      7                                        0.5         
                                                                                                   
  Extrapulmonary cryptococcosis               6                                        0.4         
                                                                                                   
  HIV encephalopathy                          5                                        0.4         
                                                                                                   
  Cachexic syndrome                           1                                        0.1         
                                                                                                   
  Pneumocystis                                1                                        0.1         
                                                                                                   
  Bacteria pneumonia                          1                                        0.1         
                                                                                                   
  Others                                      2                                        0.1         

###### 

Opportunistic Infection distribution

  Opportunistic infections                                            Sex   Frequency (N)   Percentage   
  ------------------------------------------------------------------- ----- --------------- ------------ ------
  Shingles                                                            37    93              130          25.0
                                                                                                         
  Pulmonary tuberculosis                                              41    63              104          20.0
                                                                                                         
  Oral candiasis                                                      21    42              63           12.1
                                                                                                         
  Respiratory tract infections                                        19    31              50           9.6
                                                                                                         
  Prurigo                                                             14    31              45           8.6
                                                                                                         
  Kaposi sarcoma                                                      12    18              30           5.8
                                                                                                         
  Cerebral toxoplasmosis                                              7     18              25           4.8
                                                                                                         
  Extrapulmonary tuberculosis                                         8     12              20           3.8
                                                                                                         
  Sinusitis                                                           5     5               10           1.9
                                                                                                         
  Onychomycosis                                                       2     6               8            1.5
                                                                                                         
  Esophageal candidiasis                                              5     2               7            1.3
                                                                                                         
  Pulmonary cryptococcosis                                            3     3               6            1.2
                                                                                                         
  Pharyngitis                                                         2     3               5            1.0
                                                                                                         
  HIV encephalopathy                                                  2     3               5            1.0
                                                                                                         
  Seborrheic dermatitis                                               2     2               4            0.8
                                                                                                         
  Otitis                                                              1     1               2            0.4
                                                                                                         
  Oral hairy leukoplakia                                              1     0               1            0.2
                                                                                                         
  Osteoarthritis                                                      0     1               1            0.2
                                                                                                         
  Meningitis                                                          0     1               1            0.2
                                                                                                         
  Pneumocystis                                                        0     1               1            0.2
                                                                                                         
  Recurrent bacterial pneumonia                                       0     1               1            0.2
                                                                                                         
  CMV infection                                                       0     1               1            0.2
                                                                                                         
  Other fungal infections (histoplasmosis, coccidioidomycosis etc.)   0     1               1            0.2
                                                                                                         
  Total                                                                     521             100          

3.4. Multivariate Analysis Results {#sec2-9}
----------------------------------

Our multivariate analyses confirmed the results found in our univariate analyses of the associations between OI occurrence and sex, age, and CD4 count below 200 copies/mm3. The male gender (p=0.001) and age greater than 50 years (p=0.01) were found to be significantly associated to developing and having and OI. Subjects with CD4 count less than 200 copies/mm3 were three times more susceptible to developing OIs. On the other hand, there was no association between the type of antiretroviral regimen and the onset of OI ([Table 8](#T8){ref-type="table"}).

###### 

Multivariate analysis

  Variables              Opportunistic infections   n            Odds Ratio   95% CI      P value       
  ---------------------- -------------------------- ------------ ------------ ----------- ------------- -----------
  Sex                                                                                                   
                                                                                                        
   Female                273 (27.7)                 879 (76.3)   1152         Ref                       
                                                                                                        
   Male                  146 (31.4)                 319 (68.6)   465          **1.47**    1.16-1.87     **0.001**
                                                                                                        
  Age (in years)                                                                                        
                                                                                                        
   20-29                 28 (16)                    147 (84)     175          Ref                       
                                                                                                        
   30-39                 137 (22.8)                 464 (77.2)   601          0.65        0.41-1.01     0.050
                                                                                                        
   40-49                 147 (29)                   360 (71)     507          0.62        0.50-0.78     0.000
                                                                                                        
   ≥50                   107 (32)                   227 (68)     334          **2.57**    2.44-2.71     **0.010**
                                                                                                        
  Level of Education                                                                                    
                                                                                                        
   No formal education   15 (11.9)                  39 (12.6)    54           Ref                       
                                                                                                        
   Primary               111 (88.1)                 270 (87.4)   381          0.94        0.92-1.07     0.830
                                                                                                        
   Secondary             229 (93.3)                 693 (94.7)   922          1.16        0.63-2.15     0.627
                                                                                                        
   University            64 (81)                    196 (83.4)   260          1.18        0.61-2.28     0.626
                                                                                                        
  CD4 on initiation                                                                                     
                                                                                                        
   **≥350**              56 (16.8)                  278 (83.2)   334          Ref                       
                                                                                                        
   0-199                 246 (38.6)                 392 (61.4)   638          **3.12**    2.24-4.33     **0.000**
                                                                                                        
   200-349               104 (22.1)                 366 (77.1)   470          **2.21**    1.69-2.89     **0.000**
                                                                                                        
  ARV treatment                                                                                         
                                                                                                        
   1=TDF/3TC/EFV         330 (27.2)                 885 (72.8)   1215         **Ref**                   
                                                                                                        
   2=TDF/3TC/NVP         41 (20.4)                  160 (79.6)   201          0.70        0.49-1.01     0.050
                                                                                                        
   3=AZT/3TC/NVP         22 (17.7)                  102 (82.3)   124          0.60        0.37-0.96     0.030
                                                                                                        
   4=AZT/3TC/EFV         07 (33.3)                  14 (66.7)    21           1.44        0.58-3.58     0.435
                                                                                                        
   5=AZT/3TC/LPV/r       3 (60)                     2 (40)       5            4.31        0.72-25.90    0.113
                                                                                                        
   6=AZT/3TC/ATV/r       4 (25)                     12 (75)      16           0.95        0.31-2.97     0.933
                                                                                                        
   7=TDF/3TC/LPV/r       4 (80)                     1 (20)       5            **11.54**   1.29-103.52   **0.006**
                                                                                                        
   8=TDF/3TC/ATV/r       4 (21.1)                   15 (78.9)    19           0.76        0.25-2.30     0.627
                                                                                                        
   9=ABC/3TC/LPV/r       1 (50)                     1 (50)       2            2.86        0.18-45.89    0.436
                                                                                                        
   10=ABC/3TC/ATV/r      3 (37.5)                   5 (62.5)     8            1.72        0.41-7.23     0.453

4. Discussion {#sec1-4}
=============

Although HIV is the initial causative agent of AIDS, the majority of the morbidity and mortality cases observed in immunocompromised patients result from OI due to decreased immune defenses. The objective of our study was to describe the epidemiological profile of OI in HIV-infected patients managed in accredited treatment centers (ACTs) and care/treatment units (UPEC) in the cities of Yaoundé and Douala, Cameroon.

In our study, we observed that over three quarter of those infected with HIV were women, which is consistent with the 2011 DHS data.[@ref12]. This predominance could be explained by the natural anatomical and physiological predispositions that make women more vulnerable to HIV infection. Moreover, these results are similar to the 60% obtained by a study in Ethiopia in 2013[@ref13] and to 68.8% in Togo in 2011.[@ref14] The mean age in our study was 41.27 ± 10.17 years old. This result is similar to mean age of 41 years old recorded in Dakar.[@ref15] The most represented age group was 30-39 years old. This could be explained by the high sexual activity in this age group and it similarly to the 35-39 years age-group obtained in Cameroon.[@ref16] More than half of the patients had at least a secondary education level. This result is similar to that obtained by another study in Cameroon, where 47.8% of patients had secondary education.[@ref17] Majority of the participants were single. This is consistent with the results in another study in Cameroon.[@ref17] However, these results differ from those found in India,[@ref18] as well as in Dakar, Senegal,[@ref19] where married women make up 86% and 40% of the study population. These differences could be explained by the fact that in Dakar, Senegal, the population is mostly Muslim whereas in our study, the population mostly Christian. Early marriage and polygamy is more common among Muslim population than among Christians.

More than half of the patients "discovered" their status as a result of clinical suspicion. This could be due to the fact that our study population were patients diagnosed during the "opt-in" era when HIV testing was not proposed systematically to patients. Therefore, clinicians mostly proposed HIV testing to clients when they had a clinical suspicion, leading to many people being diagnosed when they present with clinical signs and symptoms. This result corroborates that of another study in the United States, where 52% of patients had clinical signs and symptoms recognized as diagnostic grounds for HIV testing.[@ref20]

HIV1 was our most represented strain just as in prior studies.[@ref21], [@ref22] More than half of our participants had at least one symptom of HIV infection. This result is lower than that obtained in Republic of Benin, where 96.3% of patients infected with HIV were symptomatic.[@ref23] This difference could be related to the fact that in the study conducted in Benin was among patients who presented for consultation, which considerably increased their result.

The majority of our participants had a CD4 + T cell count \<200copies/mm3 which is similar to the results obtained in the United States.[@ref20] This implies that these participants are at risk of developing an advanced disease based on the WHO definition for advanced HIV disease. This finding, however, differs from that obtained in Benin, 68.8%[@ref24] and in Togo 73.8%.[@ref14] The differences may be due to the fact that these studies were done in 2004 and 2011, respectively, when the HIV/AIDS treatment initiation rates were even lower. Very few of our participants had viral load results available in their medical records. This could be explained by the fact that in 2014, viral load assay were not very accessible and were only requested when there was an immunological failure. The average viral load result was 293,558 copies/mm^3^. This value is close to what was obtained in a study on the evaluation of ART in a clinic in Rio de Janiero, Brazil,[@ref25] and implies that the majority of these patients are at risk of developing an OI. The most recent average TCD4 lymphocyte count was 412 copies/mm^3^. This result corroborates that of Dokekias et al. in Congo, who after 24 months of treatment, achieved an average TCD4 lymphocyte count of 353 copies/mm^326^. More than half of the patients were on first-line antiretroviral therapy. This is comparable to the results published in the 2016 Cameroon National AIDS Control Committee (NACC) report.

4.1. Limitations of the study {#sec2-10}
-----------------------------

Like any retrospective study, this study suffers from an information bias as some patients' clinical information and laboratory investigations results may have been lost due to poor achieving.

5. Conclusion and Global Health Implications {#sec1-5}
============================================

This study was conducted with the objective of describing the epidemiological profile of OIs in patients on treatment in accredited HIV treatment centers and care units in the cities of Yaoundé and Douala. OIs were found to be more common among people within the age group of 40 years and above and the majority were females. More than half of the patients had a CD4 count of less than 200copies/mm^3^ at baseline and the majority of patients were classified as WHO clinical stage III. Almost all the patients (95.4%) were on first-line ARV treatment. The prevalence of OI in HIV infected patients in the cities of Yaoundé and Douala was 25.9%. Factors associated with the occurrence of opportunistic infection were: gender (males), age (≥ 50 years), and CD4 count (\<200/mm^3^). These findings have implications in that there is need to place emphasis on and take implement measures to improve regular immunologic monitoring (by use of CD4 assessment) as a means to identify HIV infected patients at risk of developing OIs and hence reduce excessive dependence on clinical signs and symptoms as is the practice especially in developing countries. Finally, our findings suggest that public health interventions for reducing HIV related co-morbidities (and implicitly mortality) should especially target the male gender for greater impact in addition to other measures.

###### Key Messages

The prevalence of opportunistic infections among patients with HIV in the cities of Yaoundé and Douala, Cameroon was 25.9%.Women and HIV-infected persons above the age of 50 were found to be more affected by OIs.The most common OI was shingles which accounted for 25% of cases, followed by pulmonary tuberculosis which accounted for 25%.
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